Development and validation of a novel non-contact monitor of nocturnal respiration for identifying sleep-disordered breathing in patients with heart failure

Henry Oluwasefunmi Savage1,2, Rami N. Khushaba3*, Alberto Zaffaroni4, Michael Colefax3, Steven Farrugia3, Klaus Schindhelm3,5, Helmut Teschler6, Gerhard Weinreich6, Hartmut Grueger7, Martina Neddermann8, Conor Heneghan4, Anita Simonds1,2 and Martin R. Cowie1,2

1National Institute for Health Research Cardiovascular and Respiratory Biomedical Research Units, Royal Brompton Hospital, London, UK; 2Imperial College London, London, UK; 3ResMed Ltd., Sydney, Australia; 4ResMed Sensor Technologies, Dublin, Ireland; 5Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia; 6Department of Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; 7Clinic of Pneumology, Allergology, Sleep and Respiratory Medicine, Diakonie Kaiserswerth, Düsseldorf, Germany; 8Thorax Center Ruhrgebiet, Clinic of Pneumology and Infectiology, Evangelisches Krankenhaus Herne und Augusta-Kranken-Anstalt, Bochum, Germany

Abstract

Aims At least 50% of patients with heart failure (HF) may have sleep-disordered breathing (SDB). Overnight in-hospital polysomnography (PSG) is considered the gold standard for diagnosis, but a lack of access to such testing contributes to under-diagnosis of SDB. Therefore, there is a need for simple and reliable validated methods to aid diagnosis in patients with HF. The aim of this study was to investigate the accuracy of a non-contact type IV screening device, SleepMinderTM (SM), compared with in-hospital PSG for detecting SDB in patients with HF.

Methods and results The study included 75 adult patients with systolic HF and suspected SDB who underwent simultaneous PSG and SM recordings. An algorithm was developed from the SM signals, using digital signal processing and pattern recognition techniques to calculate the SM apnoea-hypopnoea index (AHI). This was then compared with expert-scored PSG AHI. The SM algorithm had 70% sensitivity and 89% specificity for identifying patients with clinically significant SDB (AHI > 15/h). At this threshold, it had a positive likelihood ratio of 6.3 and a negative likelihood ratio of 0.16. The overall accuracy of the SM AHI algorithm was 85.8% as shown by the area under a receiver operator characteristic curve. The mean AHI with SM was 3.8/h (95% confidence interval 0.5–7.1) lower than that with PSG.

Conclusions The accuracy of the non-contact type IV screening device SM is good for clinically significant SDB in patients with systolic HF and could be considered as a simple first step in the diagnostic pathway.

Keywords Heart failure; Sleep-disordered breathing; Apnoea-hypopnoea index; Diagnosis

Introduction

Sleep-disordered breathing (SDB) is prevalent in patients with chronic heart failure (CHF), typically occurring in ≥50% of patients [1–4]. SDB is characterized by periods of apnoea (cessation or >90% reduction in ventilation) and hypopnoea (>30% reduction in ventilation associated with oxygen desaturation of ≥4%) [5]. Importantly, SDB is associated with
increased cardiovascular morbidity and mortality, an association that persists after adjustment for other clinical predictors of outcome [1,6–8].

There are two main types of SDB: obstructive sleep apnoea (OSA), arising from repeated partial or complete closure of the oropharyngeal airway during sleep leading to repetitive hypoxia and arousals, and central sleep apnoea (CSA), characterized by an instability in ventilatory control resulting in a temporary withdrawal of central respiratory drive leading to cessation of airflow and respiratory muscle activity. Both OSA and CSA have been documented in patients with CHF. CSA may be associated with Cheyne–Stokes respiration (CSR), which consists of crescendo–decrrescendo oscillations of airflow alternating with central apnoea or hypopnoea [6].

OSA is known to be an independent risk factor for the development and progression of HF [9,10]. It may also contribute to the development of hypertension, cardiac arrhythmia, and myocardial ischaemia via a complex interplay of neurohormonal and inflammatory mechanisms [11]. CSA is generally thought to be a marker of increasing severity of CHF and may contribute to worsening symptoms of HF [12,13].

The Wisconsin Sleep cohort study estimated that 93% of women and 82% of men with symptomatic SDB were undiagnosed [14], and this proportion is likely to be similar in a HF population [15]. The current gold standard for diagnosing SDB is attended, overnight in-hospital polysomnography (PSG). This test is not always readily available and is expensive because of the need for well-equipped sleep laboratories and trained personnel who can interpret the results.

To reduce costs and provide timely diagnosis of SDB, a number of portable home monitors (PMs) have been developed but they only record a limited number of signals. PMs are usually used as an initial diagnostic or screening tool and in selected patients, if the test results are positive, can be used to recommend treatment, while ruling out additional testing if results were negative [16]. PMs can be used on an unattended basis, and several studies have reported a high diagnostic accuracy of up to 90% in detecting SDB [17–21]. High study failure rates because of their complex unattended design can, however, result in the need for repeated studies [16]. Overnight pulse oximetry and heart rate variability are some of the methods employed to screen for SDB with varying degrees of accuracy and usefulness reported [20,21].

The SleepMinder™ (SM) device is a novel non-contact type IV screening device [22] containing a biomotion sensor transceiver that uses ultra-low power radiofrequency signals to detect movement and breathing in a patient. It can be used in the patient’s home, is easy to handle, and requires minimal engagement from the patient. It is also expected to have a lower failure rate because of its non-contact design. The SM has been validated in a number of studies for measuring apnoea-hypopnoea index (AHI) in patients with suspected OSA [23,24], for scoring sleep/wake patterns [25] and CSR patterns in patients with HF [26]. However, it has not been validated for screening for SDB in patients with HF.

The aim of this study was to develop and evaluate an AHI algorithm for the SM device for screening patients with HF with suspected SDB.

**Methods**

**Study population**

Eighty adult patients underwent simultaneous SM and PSG studies as they were enrolled at three HF centres (30 patients from south-west London, UK; 28 patients from Essen and 22 patients from Herne, Germany). Five patients were excluded because of incomplete or corrupted data (one incomplete and one corrupted studies from London and three corrupted studies from Essen), leaving 75 patients with adequate paired data (>4 h) for analysis (Figure 1). No patient had undergone a diagnostic procedure for SDB before entering the study. All patients were referred to the study based on clinical judgement alone. UK volunteers were being followed up in a HF clinic and subsequently screened for SDB at the clinic. The German participants had been referred to a sleep laboratory for SDB screening. This is in accordance to the 2007 Clinical Guidelines of the portable monitoring task force of the American Academy of Sleep Medicine (AASM) [27] that

---

**Figure 1** Patients flow through the study.
recommend that portable monitors should be used on patients with a high pre-test probability for OSA. All patients had stable chronic systolic HF with a left ventricular ejection fraction (LVEF) of ≤45% based on trans-thoracic echocardiography. Patients with significant obstructive lung disease (forced expiratory volume in 1 s <50% of predicted) or those being treated with any form of positive airway pressure were excluded.

Patients gave written informed consent to participate in this study, and ethical approval was obtained from the relevant national and local committees. The study was conducted in accordance with the principles of good clinical practice and the Declaration of Helsinki.

**Overnight polysomnography**

Attended in-hospital overnight PSG was performed in sleep laboratories using standard techniques. The PSG systems used were Somnoscreen PSG Tele (Somnomedics GmbH, Germany) in the UK, Rembrandt PSG (Embla Sys Inc., USA) in Essen, and Embla S7000 PSG (Embla Sys Inc., USA) in Herne. Outputs from these PSG recording systems were similar. Thoraco-abdominal motion was measured by respiratory inductance plethysmography, and nasal airflow was monitored by nasal pressure cannula and an oral flow thermistor. Arterial oxyhaemoglobin saturation (SaO₂) was monitored by pulse oximetry. Sleep was monitored using a standard neuro electrode placement system to include electroencephalogram references (C4/A1), (C3/A2), and (O1/A2). Submental and anterior tibialis electromyograms were also recorded. Electrooculogram electrodes placed on both lateral canthi measured rapid eye movements. The transducers and lead wires permitted normal positional changes during sleep as well as movement out of bed. Bedtime was at each subject’s discretion, and PSG was terminated after final wakening.

**Polysomnography scoring**

Polysomnography studies were scored to determine PSG_{AHI} by a polysomnographic technologist using the AASM 2007 rules for respiratory events. The expert had no knowledge of the SM recordings as these were kept separate from the PSG studies. Apnoeas were defined as cessation of airflow or >90% reduction in airflow lasting ≥10 s. Hypopnoeas were defined as ≥30% reduction in airflow amplitude lasting ≥10 s with a >4% oxygen desaturation measured on pulse oximetry.

The classification of patients into CSA or OSA was based on criteria that were used in the SERVE-HF study [28,29]. Patients with clinically significant SDB (AHI ≥15/h) in whom greater than 50% of events were central, and central AHI ≥10/h were denoted as CSA patients; whereas if greater than 50% of events were obstructive, they were denoted as patients with OSA [28,29].

**SleepMinder™ recording**

The SM device (ResMed Sensor Technologies, Dublin, Ireland) is a non-contact bio-motion recording system interpreting body movement and breathing via two sinusoidal electromagnetic wave signals. The sensor operates in a licence-free band at 5.8 GHz and emits an average power of <10 mW. The signal is range gated to restrict the sensing range to a distance of 0.3 to 1.5 m.

On the night of the PSG study, the SM was positioned by the patient’s bedside at a height of 10 and 100 cm from their chest (Figure 2). It was turned on at the start of the PSG recording and then turned off at final patient wakening. SM recordings were logged onto a Secure Digital card, which was downloaded at the end of the study. The SM_{AHI} was determined from algorithms developed from the SM signals.

**Development of the SleepMinder™ AHI algorithm**

The first step was to synchronize the SM and PSG signals as accurately as possible and to create a common timestamp as the signals were recorded separately and at different sampling frequencies (16 Hz for SM and 20 Hz/32 Hz for PSG). To achieve this, a cross correlation and sliding window method was used to align feature vector transformations of the signals [30].

The SM signal was pre-processed to filter noise and remove the baseline wander (also known as de-trending). Using pattern recognition and cycle interval techniques the respiratory signal was isolated. The sleep respiratory signal was then divided into segments for AHI algorithm development and analysis. These segments, also known as epochs, are the...
time-defined segments upon which PSG is routinely scored and are typically 30 s.

An event-based algorithm was developed for the detection of SDB events (apnoeas and hypopnoeas) in the SM signals with the fundamental criteria being a ≥50% reduction in the amplitude of the non-contact measure of overall body breathing effort, lasting for ≥10 s. Severity of SDB was defined as mild (5/h ≤ AHI < 15/h), moderate (15/h ≤ AHI < 30/h), or severe (AHI ≥ 30/h).

Statistical analysis

The overnight study data were divided into two datasets. The data from the UK (n = 28) were used for SM AHI algorithm development. Results were then validated on patients from Essen and Herne (n = 47). The allocation of patients into development and validation sets based on geography potentially reduces the positive effect of any bias to site specific artefacts in the data and improves the likelihood of the test result being representative of true performance.

Normally distributed and continuous data are presented as means ± standard deviation (SD). The one-sample t-test was utilized to confirm the normal distribution of the data. The two-sample t-test was used to compare distributions of the non-paired continuous variables. For categorical variables, the chi-squared distribution was used. Algorithm development and signal analyses were performed using Matlab from Mathworks version 2011b. Statistical significance was defined as p < 0.05.

Correlation between the two AHI diagnostic tools was tested using Pearson’s correlation coefficient, and the degree of agreement was tested using a Bland and Altman analysis examining for any systematic bias in scoring by either tool. Receiver operator characteristic curves were constructed to inspect the performance of the algorithm for a selection of SDB severities.

Results

Baseline characteristics

The demographic and clinical characteristics of the recruited patients are shown in Table 1. There was some variation in the mean LVEF across the recruiting centres, but all patients had an LVEF ≤ 45% and 59% of the patients had an LVEF ≤ 35%. Patients recruited in London had milder symptoms than those recruited in Germany. LVEF was almost equivalent in the validation dataset and the development dataset, with somewhat higher use of ACE inhibitors and ß-blockers, and lower use of mineralocorticoid receptor antagonists, in the validation dataset (Table 2). In the development set 36% (10 of 28) of the patients had SDB (25% with OSA and 11% with CSA), while in the validation set 43% (20 of 47) had SDB (34% with OSA and 9% with CSA). CSR patterns were noted in PSGs from 29% (8 of 28) of the patients in the development set, with 18% having AHI < 15/h and 11% having AHI ≥ 15/h. In the validation set, 40% (19 of 47) had CSR with 17% having AHI < 15/h and 23% having AHI ≥ 15/h.

Prevalence of sleep-disordered breathing

Based on PSG findings, the prevalence of clinically-significant SDB (AHI ≥ 15/h) was 44%, with a mean AHI of 20.4/h [95% confidence interval (CI) 15.9–24.9]; 27% of patients had no SDB (AHI ≤ 5/h).

AHI algorithm performance

Correlation

There was good correlation between SM_{AHI} and PSG_{AHI}, with correlation co-efficient values of 0.93 and 0.83 (p < 0.001) in the development and validation set of patients, respectively (Figure 3).

Table 1. Demographic characteristics and clinical features of overall patients and by study centre

|                      | Overall (n = 75) | London (n = 28) | Essen (n = 25) | Herne (n = 22) |
|----------------------|-----------------|-----------------|----------------|---------------|
| Age, years (range)   | 68 (34–90)      | 69 (34–90)      | 66 (41–84)     | 70 (52–81)    |
| Male, n (%)          | 65 (87)         | 26 (93)         | 21 (84)        | 18 (82)       |
| BMI, kg/m²           | 29 ± 4.9        | 34 ± 5.5        | 29 ± 5.2       | 29 ± 3.8      |
| LVEF, %              | 34 ± 8          | 34 ± 6.2        | 29.7 ± 11.1    | 38.0 ± 6.8    |
| NYHA class ≥ III, n (%) | 49 (65)       | 8 (29)          | 20 (80)        | 21 (95)       |
| Ischaemic aetiology, n (%) | 51 (68)   | 25 (89)         | 12 (48)        | 14 (64)       |
| Diabetes mellitus, n (%) | 17 (23)     | 6 (21)          | 7 (28)         | 4 (18)        |
| COPD, n (%)          | 10 (13)         | 4 (14)          | 6 (24)         | NA            |
| Hypertension, n (%)  | 36 (48)         | 15 (54)         | 21 (84)        | NA            |
| ß-blockers, n (%)    | 60 (80)         | 21 (75)         | 21 (84)        | 18 (82)       |
| ACEi, n (%)          | 56 (75)         | 15 (54)         | 23 (92)        | 18 (82)       |
| MRA, n (%)           | 44 (59)         | 20 (71)         | 17 (68)        | 7 (32)        |

Values are mean ± standard deviation or (range), or number of patients (%).

ACEi: angiotensin converting enzyme inhibitor; BMI, body mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NA, not available; NYHA, New York Heart Association.

DOI: 10.1002/ehf2.12086
Test of agreement
A Bland–Altman plot was constructed to examine the agreement and systematic bias between the two AHI scoring techniques on the validation set (Figure 4). This plot demonstrated that the overall agreement between SM_AHI and PSG_AHI was fairly good for AHI values of <15/h. Conversely, there was consistent underscoring with SM for AHI values ≥15/h. The mean difference between the two scoring techniques was 3.8/h (95% CI 0.5–7.1, p = 0.029).

Screening accuracy
In terms of screening accuracy, the SM was 70% sensitive and 89% specific for identifying patients with clinically-significant SDB (AHI ≥15/h). It had a positive likelihood ratio (LR+) of 6.3 (positive predictive value 82.4%) and a negative likelihood ratio (LR−) of 0.16 (negative predictive value 80%). The overall accuracy of the SM AHI algorithm was 85.8% as represented by the area under a receiver operator characteristic curve constructed for this diagnostic threshold (Figure 5).

Table 2. Demographic characteristics and clinical features of development and validation group of patients

|                           | Development (n = 28) | Validation (n = 47) | P-value |
|---------------------------|---------------------|---------------------|---------|
| Age, years (range)        | 69 (34–90)          | 68 (41–84)          | 0.931   |
| Male, n (%)               | 26 (93)             | 39 (83)             | 0.223   |
| BMI, kg/m²                | 29 ± 5.5            | 29 ± 4.7            | 0.859   |
| LVEF, %                   | 34 ± 6.2            | 33.6 ± 10.1         | 0.951   |
| NYHA class ≥ III, n (%)   | 8 (29)              | 41 (87)             | <0.001  |
| Ischaemic aetiology, n (%)| 25 (89)             | 26 (55)             | 0.002   |
| Diabetes mellitus, n (%)  | 6 (21)              | 11 (23)             | 0.843   |
| β-blockers, n (%)         | 21 (75)             | 39 (83)             | 0.403   |
| ACEi, n (%)               | 15 (54)             | 41 (87)             | 0.001   |
| MRA, n (%)                | 20 (71)             | 24 (51)             | 0.081   |
| OSA, n (%)                | 7 (25)              | 16 (34)             | 0.411   |
| CSA, n (%)                | 3 (11)              | 4 (9)               | 0.751   |
| CSR, n (%)                | 8 (29)              | 19 (40)             | 0.300   |

Values are mean ± standard deviation or (range), or number of patients (%).

ACEi; angiotensin converter enzyme inhibitor; BMI, body mass index; CSA, central sleep apnoea; CSR, Cheyne-Stokes Respiration; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; OSA, obstructive sleep apnoea.

Figure 3 Pearson’s correlation coefficient plot for the validation set of patients (n = 47).

Figure 4 Bland-Altman Plot for validation set of patients (n = 47). (Shaded area represents agreement of both methods within 10 events per hour; lines represent mean difference and 95% upper and lower confidence intervals for the difference).
performance of the algorithm was improved for the most severe disease threshold of AHI $\geq 30$/h (sensitivity 82%, specificity 97%, LR+: 29, LR−: 0.03, AUC 92%).

**Misclassification rate according to treatment**

The misclassification rate (MRrx) of the SM device was calculated according to the commonly used treatment threshold of AHI $\geq 15$/h. Compared with expertly scored PSG, SM misclassified 9/47 (19%) patients in the validation set [AHI $< 15$/h ($n = 6$) and AHI $\geq 15$/h ($n = 3$)].

**Discussion**

This study describes the development and validation of an algorithm using signals obtained from the SM type IV screening device and showed that it is capable of identifying SDB (based on the AHI) with a good overall diagnostic accuracy in patients with chronic systolic HF and a prior suspicion of SDB. The prevalence of SDB (AHI $\geq 15$/h) was 44%, which is comparable to that reported in previous studies [1–4]. SM/PSG signals from 80 patients were successfully collected. Exclusion of data from five patients was because of poor signal quality. The failure rate for SM was therefore 6.25%, which is comparable to contact devices used either at home, or in-hospital [16]. Refinement of the hardware and algorithm could lower the failure rate.

A positive SM result was associated with a high likelihood of clinically relevant SDB (LR+ 6.3). With the false positive rate of 6%, three patients in this cohort would have been incorrectly identified as having SDB. Conversely, only 16% of patients with a negative SM test actually had SDB (LR− 0.16). In general, portable monitors should be used to increase the pre-test probability to a sufficiently high post-test probability that one is very confident that the patient has OSA. As the relationship between the pre-test and post-test probability can be described by the LRs, it can be claimed that the SM device is capable of detecting SDB in patients with HF with a good accuracy at a threshold of AHI $\geq 15$/h. The SM device may therefore have the greatest utility as a first step in identifying patients with a high probability of SDB and appropriately prioritize them for a formal PSG study.

In general, at an AHI threshold of $<15$/h, the SM performed well, although there was some underestimation (16%) at thresholds of $\geq 15$/h. A potential explanation for this underestimation is the coincidence of body movements and respiratory events at higher AHI levels. The SM algorithm focuses on separating respiratory-related movement patterns from other movement-related patterns, e.g. limb movement (LM). Therefore, at higher apnoea/hypopnoea event rates, the SM algorithm may flag a number of events as LM rather than SDB events resulting in lower AHI values. However, the high sensitivity and specificity of the SM device at AHI values of $\geq 30$/h indicate that even if AHI is underscored in some patients, the majority were still assigned to the appropriate SDB category. As an example, of the 47 studies in the validation set, 11 had an AHI of $\geq 30$/h based on expert scoring of PSG data. Of these 11 studies, only two were misclassified by the SM algorithm (one as mild and one as moderate). The mild classification recording was entirely dominated by LMs of both legs, while the moderate classification recording was also affected by LMs, but to a lesser extent. As both of these studies had a high AHI and a large number of LMs, there were numerous instances where LMs coincided with breathing events. In disregarding LMs, the SM algorithm also therefore missed the overlapping breathing event.

The performance of SM in detecting and screening SDB in this HF cohort was comparable to other forms of portable/home contact screening devices [14–19]. However, most of these studies only included patients without HF. Two studies were performed on patients with a high clinical suspicion of OSA using ApneaLink™ as an SDB screening tool [31,32]. In both studies the accuracy of the automatic scoring of the contact-based type IV ApneaLink™ on patients without HF was comparable to that of the non-contact type IV SM performance reported in this paper (sensitivity–specificity of 64–94% and 89–60% for [31] and [32], respectively). An alternative study on patients with HF using oxygen saturations to determine the presence of SDB reported slightly better performance (sensitivity–specificity of 93–73%) [19].

A SM study is likely to be less costly and easier to perform than overnight in-hospital PSG and is more convenient for patients. Given that SM is non-contact, it is unlikely to influence...
sleeping and is likely to be acceptable to patients. As a result, use of the SM for multiple nights could be possible as part of the diagnostic process for clinically important SDB. This means that the SM offers the potential to document variations in SDB metrics over much longer monitoring periods and improve understanding of how these physiological parameters influence or are influenced by the course of HF over time.

A future enhancement could be the ability to discriminate between obstructive and central events, which is important in the selection of an appropriate treatment. Treatment of predominant CSA in patients with HF has been shown to increase mortality [28]. At the current stage of development, limitations exist in using the SM technology for this application because the sensor is a movement detector and it can be difficult to separate respiratory movement from other sources of movement.

This study was a pilot study, and further studies are required to confirm the result in the wider HF population. This study included only patients with reduced LVEF, and so the results may not be generalizable to those who have HF with preserved ejection fraction, who also have a high incidence of SDB [33]. Future studies need to include a higher proportion of female samples given the predominantly male sample included in this trial.

In conclusion, in addition to being able to detect SDB in patients without HF, the results of this study show that the non-contact type IV screening device SM can be used to identify SDB in patients with systolic HF with good accuracy. By identifying patients with HF most likely to have SDB as suitable for referral for further diagnostic study (e.g. PSG), SM could reduce pressure on limited sleep service resources. This is particularly relevant if demand for these services increases based on the results of multinational randomized control trials investigating the morbidity and mortality benefits of treating SDB in patients with HF [29].

Acknowledgements
Editing assistance was provided by Nicola Ryan, independent medical writer, funded by ResMed.

Conflict of interest
H.S.’s salary was funded for research by ResMed through a grant to Imperial College. M.R.C. received research funding and consultancy fees from ResMed. H.T. receives a study grant, travelling expenses, and honorarium for invited lectures from ResMed. H.G. received financial support from ResMed only for medical talks. R.N.K., A.Z., M.C., S.F. and K.S. are all employed by ResMed. G.W., A.K.S. and M.D. have no conflicts of interest to declare.

Funding
This work was supported by ResMed Ltd, Australia.

References
1. Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler L, Roselle GA. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. *Circulation* 1998; 97: 2154–2159.
2. Paulino A, Dany T, Margarit L, Stoica M, Deswarte G, Khouri I, Vermes E, Meizels A, Hittinger L, d’Ortho MP. Prevalence of sleep-disordered breathing in a 316-patient French cohort of stable congestive heart failure. *Arch Cardiovasc Dis* 2009; 102: 169–175.
3. Oldenberg O, Lamp B, Faber L, Teschler H, Horstkotte D, Topler V. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. *Eur J Heart Fail* 2007; 9: 251–257.
4. Vazir A, Hastings PC, Dayer M, McIntyre HF, Henein MY, Poole-Wilson PA, Cowie MR, Morrell MJ, Simonds AK. A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction. *Eur J Heart Fail* 2007; 9: 243–250.
5. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SP, Redline S, Strohl KP, Davidson Ward SL, Tangué MM, American Academy of Sleep Medicine. Sleep M. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med* 2012; 8: 597–619.
6. Lanfranchi PA, Braghiroli A, Bosimini E, Gnemmi M, Giannuzzi P. Sleep and exertional periodic breathing in chronic heart failure: prognostic importance and interdependence. *Circulation* 2006; 113: 44–50.
7. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005; 365: 1046–1053.
8. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T, American Heart Association Council on High Blood Pressure Research Professional Education Committee CoCC, American Heart Association Stroke C, American Heart Association Council on Cardiovascular N, American College of Cardiology F. Sleep apnea and cardiovascular disease: an American Heart Association/American College of
Cardiovascular Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118: 1080–1111.

10. Gottlieb DJ, Yenokyan G, Newman AB, O’Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, Shahar E. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122: 352–360.

11. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahadevan J, Redline S, Sleep Heart Health S. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173: 910–916.

12. Bradley TD, Flora JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation 2003; 107: 1822–1826.

13. Oldenburg O, Bitter T, Wiemer M, Langer C, Horstkotte D, Piper C. Pulmonary arterial pressure in heart failure patients with sleep-disordered breathing. Sleep Med 2009; 10: 726–730.

14. Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 1997; 20: 705–706.

15. Javaheri S, Carel EB, Chen E, Tong KB, Abraham WT. Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med 2011; 183: 539–546.

16. Flemons WW, Littner MR, Rowley JA, Gay P, Anderson WM, Hudgel DW, McEvoy RD, Loubé DJ. Home diagnosis of sleep apnea: a systematic review of the literature. An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest 2003; 124: 1543–1579.

17. Ng SS, Chan TO, To KW, Ngai J, Tung A, Ko FW, Hui DS. Validation of Embletta portable diagnostic system for identifying patients with suspected obstructive sleep apnoea syndrome (OSAS). Respirology 2010; 15: 336–342.

18. Quintana-Gallego E, Villa-Gil M, Carmona-Bernal C, Botebol-Benhamou G, Martinez-Martínez A, Sanchez-Armengol A, Polo-Padillo J, Capote F. Home respiratory polygraphy for diagnosis of sleep-disordered breathing in heart failure. Eur Respir J 2004; 24: 443–448.

19. Weinreich G, Armitstead J, Topfer V, Wang YM, Wang Y, Teschler H. Validation of ApneaLink as screening device for Cheyne-Stokes respiration. Sleep 2009; 32: 553–557.

20. Hayano J, Tsukahara T, Watanabe E, Sasaki F, Kawai K, Sakakibara H, Kodama I, Nomiyaama T, Fujimoto K. Accuracy of ECG-based screening for sleep-disordered breathing: a survey of all male workers in a transport company. Sleep Breath 2013; 17: 243–251.

21. Ward NR, Cowie MR, Rosen SD, Roldao V, De Villa M, McDonagh TA, Simonds A, Morrell MJ. Utility of overnight pulse oximetry and heart rate variability analysis to screen for sleep-disordered breathing in chronic heart failure. Thorax 2012; 67: 1000–1005.

22. Practice parameters for the use of portable recording in the assessment of obstructive sleep apnea. Standards of Practice Committee of the American Sleep Disorders Association. Sleep 1994; 17: 372–377.

23. Zaffaroni A, Kent B, O’Hare E, Heneghan C, Boyle P, O’Connell G, Pallin M, de Chazal P, McNicholas WT. Assessment of sleep-disordered breathing using a non-contact bio-motion sensor. J Sleep Res 2013; 22: 231–236.

24. Weinreich G, Terjung S, Wang Y, Werther S, Zaffaroni A, Teschler H. Validation of SleepMinder as screening device for obstructive sleep apnea: Validierung von SleepMinder als Screeninggerät für die obstruktive Schlafapnoe. Sommologie: Schlaforschung und Schlafmedizin 2014; 18: 238–242.

25. De Chazal P, Fox N, O’Hare E, Heneghan C, Zaffaroni A, Boyle P, Smith S, O’Connell C, McNicholas WT. Sleep/wake measurement using a non-contact biomotion sensor. J Sleep Res 2011; 20: 356–366.

26. Savage HO, Khushaba R, Bateman P, Farrugia S, Schindhelm K, Simonds AK, Cowie MR. Cheyne stokes respiration in patients with heart failure detected by a novel non-contact monitor of nocturnal respiration. Eur J Heart Fail 2013; 15: S1–S2.

27. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hudgel D, Sateia M, Schwab R, Portable Monitoring Task Force of the American Academy of Sleep M. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007; 3: 737–747.

28. Cowie MR, Woehrle H, Wegscheider K, Angermann C, O’Drorho MP, Erdemann E, Levy P, Simonds AK, Somers VK, Zannad F, Teschler H. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015; 373: 1095–1105.

29. Cowie MR, Woehrle H, Wegscheider K, Angermann C, O’Drorho MP, Erdemann E, Levy P, Simonds A, Somers VK, Zannad F, Teschler H. Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure. Eur J Heart Fail 2013; 15: 937–943.

30. Smith SW. The Scientist and Engineer’s Guide to Digital Signal Processing. 2nd ed. San Diego: California Technical Publishing; 1999.

31. BaHamam AH, Sharif M, Gacuan DE, George S. Evaluation of the accuracy of manual and automatic scoring of a single airflow channel in patients with a high probability of obstructive sleep apnea. Med Sci Monit 2011; 17: MT13–MT19.

32. Ngco CA, Dibor E, Aimaretty S, Gonzalez S, Rhodius E. Comparison of the automatic analysis versus the manual scoring from ApneaLink device for the diagnosis of obstructive sleep apnoea syndrome. Sleep Breath 2011; 15: 679–686.

33. Bitter T, Faber L, Herwig D, Langer C, Horskotke D, Oldenburg O. Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009; 11: 602–608.